#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2996	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2525	274.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1918	1918	T	369	T,G,C	312,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2996	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2525	274.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1652	1652	C	412	C,G,A	360,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	773	5102	23S	2890	490	100.0	23S.l15.c30.ctg.1	1273	123.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	773	5102	23S	2890	2647	99.92	23S.l15.c30.ctg.2	3039	327.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1094	1094	A	350	A,G	310,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	773	5102	23S	2890	2647	99.92	23S.l15.c30.ctg.2	3039	327.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	1728	1728	C	391	C,T	360,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	773	5102	23S	2890	2647	99.92	23S.l15.c30.ctg.2	3039	327.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	1802	1802	A	401	A	361	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	773	5102	23S	2890	2647	99.92	23S.l15.c30.ctg.2	3039	327.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2354	2354	C	406	C,A,G	368,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	498	folP	855	855	100.0	folP.l6.c17.ctg.1	1841	63.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1221	1223	AGC	77;77;77	A;G;C	72;73;72	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	856	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3389	59.0	1	SNP	p	S91F	1	.	.	271	273	TTC	696	698	TTC	59;59;59	T;T;C	56;54;57	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	856	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3389	59.0	1	SNP	p	D95G	1	.	.	283	285	GGC	708	710	GGC	60;60;60	G;G;C	58;57;56	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	856	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3389	59.0	1	SNP	p	G95N	0	.	.	283	285	GGC	708	710	GGC	60;60;60	G;G;C	58;57;56	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	202	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1806	25.6	1	SNP	p	G45D	0	.	.	133	135	GGC	759	761	GGC	61;61;61	G;G;C	51;49;52	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	186	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1543	28.4	0	.	n	.	0	A197.	DEL	197	197	A	869	869	A	63	A	54	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	684	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3501	46.1	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1825	1827	GTC	77;78;78	G;T;C	69;68;72	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	684	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3501	46.1	1	SNP	p	D86N	0	.	.	256	258	GAC	931	933	GAC	50;50;50	G,C;A;C	37,1;24;32	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	684	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3501	46.1	1	SNP	p	R87I	0	.	.	259	261	CGT	934	936	CGT	48;48;45	C;G;T	37;30;29	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	684	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3501	46.1	1	SNP	p	S87R	1	.	.	259	261	CGT	934	936	CGT	48;48;45	C;G;T	37;30;29	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	684	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3501	46.1	1	SNP	p	R87W	0	.	.	259	261	CGT	934	936	CGT	48;48;45	C;G;T	37;30;29	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	684	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3501	46.1	1	SNP	p	S88P	0	.	.	262	264	TCC	937	939	TCC	45;43;43	T;C;C	37;35;34	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	830	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3255	61.1	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1669	1671	TGC	82;82;83	T;G;C	70;74;72	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	830	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3255	61.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1879	1881	GGC	58;59;58	G;G;C	52;52;47	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1298	1300	GCA	94;94;94	G;C;A,C	84;80;78,1	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1301	1303	ATC	94;94;94	A;T;C	82;86;86	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1313	1315	GTG	96;96;96	G;T,G;G	87;85,1;88	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1313	1315	GTG	96;96;96	G;T,G;G	87;85,1;88	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1817	1819	ACC	57;57;57	A,C;C;C,G	39,1;49;51,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1871	1873	GCG	40;38;39	G;C,G;G	32;26,1;29	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1871	1873	GCG	40;38;39	G;C,G;G	32;26,1;29	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1994	1996	GGC	43;43;44	G;G;C,T	39;40;40,2	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2003	2005	GGC	37;37;37	G;G;C	35;29;22	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	564	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2316	54.1	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2021	2023	TCG	35;35;35	T,G;C;G,C	25,1;29;31,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	622	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3412	40.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1759	1761	CCG	60;59;57	C,G,T,A;C,G;G,C	45,1,1,1;49,1;35,4	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	250	porA	1146	1146	99.56	porA.l6.c4.ctg.1	1848	31.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	379	379	C	25	C	20	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	527	529	GAA	49;49;49	G;A;A,C	45;45;44,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	815	817	GAT	48;54;55	G;A;T	42;48;48	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	938	940	TCA	54;54;54	T;C;A,C	51;51;50,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1067	1069	GTC	40;41;42	G;T,C;C,T	36;35,1;36,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1397	1399	GCA	25;25;25	G;C;A,C	21;21;20,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	1	SNP	p	G120K	1	.	.	358	360	AAG	773	775	AAG	52;52;52	A;A;G	47;49;47	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	1	SNP	p	A121D	1	.	.	361	363	GAC	776	778	GAC	53;52;52	G;A;C	49;47;48	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	258	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1657	34.2	1	SNP	p	D121N	0	.	.	361	363	GAC	776	778	GAC	53;52;52	G;A;C	49;47;48	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1048	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4769	50.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1774	1776	AAT	57;56;56	A;A;T	53;52;51	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	130	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1362	22.3	1	SNP	p	V57M	1	.	.	169	171	ATG	779	781	ATG	46;46;46	A;T;G	40;40;40	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
